These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 12165902)

  • 1. [Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantation can be prevented by donor lymphocyte infusion in a critical stage of increasing mixed chimerism].
    Beck JF; Klingebiel T; Kreyenberg H; Schaudt A; Wölle W; Niethammer D; Bader P
    Klin Padiatr; 2002; 214(4):201-5. PubMed ID: 12165902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?
    Bader P; Kreyenberg H; Hoelle W; Dueckers G; Handgretinger R; Lang P; Kremens B; Dilloo D; Sykora KW; Schrappe M; Niemeyer C; Von Stackelberg A; Gruhn B; Henze G; Greil J; Niethammer D; Dietz K; Beck JF; Klingebiel T
    J Clin Oncol; 2004 May; 22(9):1696-705. PubMed ID: 15117992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
    Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
    Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy.
    Bader P; Niemeyer C; Willasch A; Kreyenberg H; Strahm B; Kremens B; Gruhn B; Dilloo D; Vormoor J; Lang P; Niethammer D; Klingebiel T; Beck JF
    Br J Haematol; 2005 Mar; 128(5):649-58. PubMed ID: 15725087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective.
    Bader P; Kreyenberg H; Hoelle W; Dueckers G; Kremens B; Dilloo D; Sykora KW; Niemeyer C; Reinhardt D; Vormoor J; Gruhn B; Lang P; Greil J; Handgretinger R; Niethammer D; Klingebiel T; Beck JF
    Bone Marrow Transplant; 2004 Apr; 33(8):815-21. PubMed ID: 14990984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children.
    Bader P; Klingebiel T; Schaudt A; Theurer-Mainka U; Handgretinger R; Lang P; Niethammer D; Beck JF
    Leukemia; 1999 Dec; 13(12):2079-86. PubMed ID: 10602432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia.
    Barrios M; Jiménez-Velasco A; Román-Gómez J; Madrigal ME; Castillejo JA; Torres A; Heiniger A
    Haematologica; 2003 Jul; 88(7):801-10. PubMed ID: 12857560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children.
    Gorczyñska E; Turkiewicz D; Toporski J; Kalwak K; Rybka B; Ryczan R; Sajewicz L; Chybicka A
    Bone Marrow Transplant; 2004 Jan; 33(2):211-7. PubMed ID: 14628077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.
    Lutz C; Massenkeil G; Nagy M; Neuburger S; Tamm I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2008 May; 41(9):805-12. PubMed ID: 18195682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved.
    Massenkeil G; Nagy M; Lawang M; Rosen O; Genvresse I; Geserick G; Dörken B; Arnold R
    Bone Marrow Transplant; 2003 Mar; 31(5):339-45. PubMed ID: 12634724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of serial quantitative analysis of hematopoietic chimerism after allogeneic stem cell transplantation in children for severe aplastic anemia.
    Hoelle W; Beck JF; Dueckers G; Kreyenberg H; Lang P; Gruhn B; Führer M; Niethammer D; Klingebiel T; Bader P
    Bone Marrow Transplant; 2004 Jan; 33(2):219-23. PubMed ID: 14647253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: is there an option to prevent relapse?
    Bader P; Beck J; Schlegel PG; Handgretinger R; Niethammer D; Klingebiel T
    Bone Marrow Transplant; 1997 Jul; 20(1):79-81. PubMed ID: 9232263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
    Koldehoff M; Steckel NK; Hlinka M; Beelen DW; Elmaagacli AH
    Am J Hematol; 2006 Oct; 81(10):735-46. PubMed ID: 16838323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
    van der Straaten HM; van Biezen A; Brand R; Schattenberg AV; Egeler RM; Barge RM; Cornelissen JJ; Schouten HC; Ossenkoppele GJ; Verdonck LF;
    Haematologica; 2005 Oct; 90(10):1339-45. PubMed ID: 16219570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow.
    Garderet L; Labopin M; Gorin NC; Polge E; Fouillard L; Ehninger GE; Ringden O; Finke J; Tura S; Frassoni F
    Bone Marrow Transplant; 2003 Jan; 31(1):23-9. PubMed ID: 12621503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.